Philadelphia chromosome-positive acute myeloid leukemia: A rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis

American Journal of Clinical Pathology

Volumn 127, Issue 4, 2007, Pages 642-650

  Soupir, Chad P ^a   Vergilio, Jo Anne ^b   Dal Cin, Paola ^b   Muzikansky, Alona ^a   Kantarjian, Hagop ^c   Jones, Dan ^c   Hasserjian, Robert P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytogenetics; Genetics; Hematopathology; Leukemia; Philadelphia chromosome

Indexed keywords

BCR ABL PROTEIN; GEMTUZUMAB OZOGAMICIN; IMATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34247169583     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/B4NVER1AJJ84CTUU     Document Type: Article

References (45)

1. Keung YK, Beaty M, Powell BL, et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia: retrospective study and review of literature. Leuk Res. 2004;28:579-586.
2. Paietta E, Racevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia. 1998;12:1881-1885.
3. Cuneo A, Ferrant A, Michaux JL, et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica. 1996;81:423-427.
4. Berger R. Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia. Leuk Lymphoma. 1993;11(suppl 1):235-237.
5. Bloomfield CD, Lindquist LL, Brunning RD, et al. The Philadelphia chromosome in acute leukemia. Virchows Arch B Cell Pathol. 1978;29:81-91.
6. Tien HF, Wang CH, Chuang SM, et al. Characterization of Philadelphia-chromosome-positive acute leukemia by clinical, immunocytochemical, and gene analysis. Leukemia. 1992;6:907-914.
7. Whang-Peng J, Henderson ES, Knutsen T, et al. Cytogenetic studies in acute myelocytic leukemia with special emphasis on the occurrence of Ph1 chromosome. Blood. 1970;36:448-457.
8. Killick S, Matutes E, Powles RL, et al. Outcome of biphenotypic acute leukemia. Haematologica. 1999;84:699-706.
9. Legrand O, Perrot JY, Simonin G, et al. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein overexpression. Br J Haematol. 1998;100:147-155.
10. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
11. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
12. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:351. World Health Organisation Classification of Tumours.
13. Bauermeister DE. Quantitation of bone marrow reticulin: a normal range. Am J Clin Pathol. 1971;56:24-31.
14. Preffer FL. Diagnostic Immunopathology. 2nd ed. New York, NY: Raven Press; 1995:725-749.
15. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432.
16. Giles FJ, Cortes JE, Kantarjian HM, et al. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:753-774, xii.
17. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
18. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. [published correction appears in N Engl J Med. 1999;341:1484]. N Engl J Med. 1999;341:1051-1062.
19. Tuzuner N, Cox C, Rowe JM, et al. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leuk Res. 1994;18:559-564.
20. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185-190.
21. Thiele J, Laubert A, Vykoupil KF, et al. Autopsy and clinical findings in acute leukemia and chronic myeloproliferative diseases: an evaluation of 104 patients. Pathol Res Pract. 1985;179:328-336.
22. Grimwade D, Walker H, Oliver F, et al, for the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
23. Kantarjian H, O'Brien S, Cortes J, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003;98:81-85.
24. Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, et al. Chemotherapy-related - late occurring - Philadelphia chromosome in AML, ALL and CML: similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia. 1997;11:1571-1574.
25. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:671-684, x.
26. Przepiorka D, Thomas ED. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1988;3:113-119.
27. Rowley JD. Ph1-positive leukaemia, including chronic myelogenous leukaemia. Clin Haematol. 1980;9:55-86.
28. Diez-Martin JL, Dewald GW, Pierre RV. Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic leukemia. Am J Hematol. 1988;27:194-203.
29. Maddox AM, Keating MJ, Trujillo J, et al. Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapy. Leuk Res. 1983;7:509-522.
30. Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991;78:2411-2418.
31. Kurzrock R, Kantarjian HM, Druker BJ, et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138:819-830.
32. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375-2384.
33. Pane F, Intrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21:8652-8667.
34. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003;17:691-699.
35. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
36. Vogler WR, Velez-Garcia E, Weiner RS. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103-1111.
37. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
38. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
39. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005;103:1659-1669.
40. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.
41. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 2002;99:2304-2309.
42. Ito K, Tominaga K, Suzuki T, et al. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol. 2005;81:242-245.
43. Jentsch-Ullrich K, Pelz AF, Braun H, et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologca. 2004;89:ECR15. Available at http://www.haematologica.org/online/e-cases/2004/5/ecr15/index.htm. Accessed May 1, 2006.
44. Yamaguchi M, Konishi I. Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia [in Japanese]. Rinsho Ketsueki. 2003;44:254-256.
45. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol. 2002;117:360-367.